» Articles » PMID: 16639080

BRCA1 Downregulation Leads to Premature Inactivation of Spindle Checkpoint and Confers Paclitaxel Resistance

Overview
Journal Cell Cycle
Specialty Cell Biology
Date 2006 Apr 28
PMID 16639080
Citations 55
Authors
Affiliations
Soon will be listed here.
Abstract

BRCA1 germline mutations predispose women to early onset, familial breast and ovarian cancer. BRCA1 has been recently implicated in the cellular response to agents that disrupt the mitotic spindle. In this report, we studied BRCA1 contribution to paclitaxel response in MCF-7 breast cancer cells. We show that MCF-7 cells transfected with BRCA1 siRNA display a significant increase in resistance to paclitaxel compared with the control cells. We next demonstrate that downregulation of BRCA1 reduces the mitotic index and triggers premature cyclin B1 degradation and decrease in Cdk1 activity following paclitaxel treatment, suggesting that BRCA1 downregulation results in precocious inactivation of the spindle checkpoint. These findings were confirmed by showing that BRCA1 downregulation induces premature sister-chromatids separation in MCF-7 cells following spindle damage. Furthermore, we show that BRCA1 up-regulates the expression of the protein kinase BubR1, essential component of the functional spindle checkpoint, whose downregulation is known to result in paclitaxel resistance in MCF-7 cells. Altogether, our findings support the notion that downregulation of BRCA1 expression mediates paclitaxel resistance through premature inactivation of spindle checkpoint in MCF-7 breast cancer cells. They link BRCA1 to the mitotic checkpoint that plays an essential role in the maintenance of chromosomal stability.

Citing Articles

Key genes and molecular mechanisms related to Paclitaxel Resistance.

Alalawy A Cancer Cell Int. 2024; 24(1):244.

PMID: 39003454 PMC: 11245874. DOI: 10.1186/s12935-024-03415-0.


Case report: Emerging BRCA mutation confers benefit from olaparib after chemotherapy intolerance in advanced triple-negative breast cancer.

Shen X, Wu J, Li J, Shao X, Wang X Clin Case Rep. 2024; 12(4):e8680.

PMID: 38571902 PMC: 10988688. DOI: 10.1002/ccr3.8680.


PP2A inhibition causes synthetic lethality in BRCA2-mutated prostate cancer models via spindle assembly checkpoint reactivation.

Wang J, Chen Y, Li S, Liu W, Zhou X, Luo Y J Clin Invest. 2023; 134(1).

PMID: 37934606 PMC: 10760972. DOI: 10.1172/JCI172137.


Mechanisms of cancer cell death induction by paclitaxel: an updated review.

Zhao S, Tang Y, Wang R, Najafi M Apoptosis. 2022; 27(9-10):647-667.

PMID: 35849264 DOI: 10.1007/s10495-022-01750-z.


Breast cancer: Muscarinic receptors as new targets for tumor therapy.

Espanol A, Salem A, Sanchez Y, Sales M World J Clin Oncol. 2021; 12(6):404-428.

PMID: 34189066 PMC: 8223712. DOI: 10.5306/wjco.v12.i6.404.